J Clin Oncol
3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study
Kamdar M, Solomon SR, Arnason J, et al
In this article, the authors report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel versus standard of care for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma. These results confirmed superior and more durable efficacy with lisocabtagene maraleucel versus standard of care, support lisocabtagene maraleucel as an effective second-line treatment for relapsed/refractory LBCL.
Previous Article
- • 3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study
- • Final Results of the Phase 2 PILOT Study in Relapsed/Refractory Large B-Cell Lymphoma
- • Case Series: Lisocabtagene Maraleucel for Richter’s Transformation
- • Real-World Analysis of Lisocabtagene Maraleucel for Relapsed/Refractory Large B-cell Lymphoma
- • Implementation of a Lisocabtagene Maraleucel Outpatient Monitoring Program
- • Lisocabtagene Maraleucel Versus Second-Line Chemotherapy Regimens in the Real World
- • Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
- • Idecabtagene Vicleucel in Patients With Relapsed/Refractory Multiple Myeloma
- • Outcomes of Older Adults and Frail Patients Treated With Idecabtagene Vicleucel
- • Idecabtagene Vicleucel for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- • KarMMa-3 Analyses: Idecabtagene Vicleucel in Triple Class-Exposed RRMM
- • Real-World Experience: Idecabtagene Vicleucel in Older Patients With Multiple Myeloma
